Skip to Main Content

Author Details

Daniel E Ball
Lilly Research Laboratories
2000
26
13
PMIDPaper TitleJournal TitlePublished Year
36478657A framework for addressing Alzheimer's disease: Without a frame, the work has no aim.Alzheimers Dement2023
29154268Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease.J Alzheimers Dis2018
30326851Retrospective assessment of patient characteristics and healthcare costs prior to a diagnosis of Alzheimer's disease in an administrative claims database.BMC Geriatr2018
27574722Treatment patterns and cost-effectiveness of first line treatment of advanced non-squamous non-small cell lung cancer in Medicare patients.J Med Econ2017
28329147A Claims-Based Examination of Health Care Costs Among Spouses of Patients With Alzheimer's Disease.J Gerontol A Biol Sci Med Sci2017
27400711Assessing the economic burden of Alzheimer's disease patients first diagnosed by specialists.BMC Geriatr2016
29214279Bridging the Gap between Research and Clinical Practice in Asymptomatic Alzheimer's Disease.J Prev Alzheimers Dis2016
26671598Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma.J Med Econ2016
25907619Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.Clin Ther2015
24892175Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies.Pharmacoepidemiol Drug Saf2014
25001114Using U.S. Medicare records to evaluate the indirect health effects on spouses: a case study in Alzheimer's disease patients.BMC Health Serv Res2014
21294993Increased olanzapine discontinuation and health care resource utilization following a Medicaid policy change.J Clin Psychiatry2011
22084895Persistence with biologic therapies in the Medicare coverage gap.Am J Manag Care2011
21616722Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.Am J Geriatr Pharmacother2011
20109170Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia.BMC Psychiatry2010
20694186Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophrenia.Patient Prefer Adherence2010
20919595Costs associated with attempted suicide among individuals with bipolar disorder.J Ment Health Policy Econ2010
18381404Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change.Health Aff (Millwood)2008
17207305Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs.Curr Med Res Opin2007
16187769The economic burden of schizophrenia in the United States in 2002.J Clin Psychiatry2005
15640631The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.Crit Care Med2004
15640632Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial.Crit Care Med2004
12544986Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.Crit Care Med2003
11209450A comparison of abciximab use in MCO and non-MCO populations.Am J Manag Care2001
10785670Shorter hospital stays for angioplasty patients who receive abciximab.J Invasive Cardiol2000
11227396Association between abciximab and length of stay in intensive care for patients undergoing percutaneous coronary intervention. A 2-stage econometric model in a naturalistic setting.Pharmacoeconomics2000
  • 1 - 26 of 26

Recommended Authors

Johns Hopkins Bloomberg School of Public Health
Career Start Year 2012
Number of shared co-authors 0
AbbVie Inc.
Career Start Year 2007
Number of shared co-authors 0
Analysis Group Inc.
Career Start Year 2007
Number of shared co-authors 0
Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital
Career Start Year 2005
Number of shared co-authors 0
Axtria Inc.
Career Start Year 2005
Number of shared co-authors 0
Harvard Medical School and the Harvard Pilgrim Health Care Institute
Career Start Year 2004
Number of shared co-authors 0
Mayo Clinic
Career Start Year 2002
Number of shared co-authors 0
University of Pennsylvania Perelman School of Medicine
Career Start Year 2002
Number of shared co-authors 0
Rutgers University Institute for Health, the State University of New Jersey
Career Start Year 2001
Number of shared co-authors 0
Mongan Institute, Massachusetts General Hospital and Harvard Medical School
Career Start Year 1999
Number of shared co-authors 0
Duke Clinical Research Institute
Career Start Year 1999
Number of shared co-authors 0
University of Washington
Career Start Year 1997
Number of shared co-authors 0
School of Public Health, The University of Texas Health Science Center at Houston
Career Start Year 1997
Number of shared co-authors 0
Duke University
Career Start Year 1997
Number of shared co-authors 0
University of Texas Medical Branch at Galveston
Career Start Year 1997
Number of shared co-authors 0
Division of Pharmacoepidemiology, Brigham & Women's Hospital, Harvard Medical School
Career Start Year 1996
Number of shared co-authors 0
Stanford University School of Medicine
Career Start Year 1996
Number of shared co-authors 1
Mayo Clinic
Career Start Year 1996
Number of shared co-authors 0
Institute of General Practice and Family Medicine, University Hospital
Career Start Year 1996
Number of shared co-authors 0
Harvard T.H. Chan School of Public Health
Career Start Year 1995
Number of shared co-authors 0
University of Southern California
Career Start Year 1992
Number of shared co-authors 0
University of Massachusetts Chan Medical School
Career Start Year 1991
Number of shared co-authors 0
Data Sciences Institute, Takeda Pharmaceuticals International Inc.
Career Start Year 1990
Number of shared co-authors 0
university of massachusetts amherst Chan Medical School
Career Start Year 1988
Number of shared co-authors 0
Harvard Medical School
Career Start Year 1988
Number of shared co-authors 1
Weill Cornell Medical College
Career Start Year 1987
Number of shared co-authors 0
Institute of Health Policy, University of Toronto
Career Start Year 1984
Number of shared co-authors 0
Brigham and Women's Hospital
Career Start Year 1982
Number of shared co-authors 0
University of Iowa, School of Public Health
Career Start Year 1982
Number of shared co-authors 0
University of Toronto
Career Start Year 1977
Number of shared co-authors 1

Collaborators

Centre Hospitalier Regional Mons-Hainaut
Co-authored papers 3
University of Pittsburgh Medical Center
Co-authored papers 3
The CRISMA Laboratory (Clinical Research, University of Pittsburgh
Co-authored papers 2
Clinical and Translational Science Institute, University of Florida
Co-authored papers 2
Vanderbilt University
Co-authored papers 2
Vanderbilt University Medical Center
Co-authored papers 2
University of Florida
Co-authored papers 2
University of Pittsburgh
Co-authored papers 2
Lilly Research Laboratories
Co-authored papers 1
Universite Paris Descartes
Co-authored papers 1
Howard Levy Consulting LLC
Co-authored papers 1
University of Sheffield
Co-authored papers 1
Banner Alzheimer's Institute, University of California
Co-authored papers 1
The Clinical Research, University of Pittsburgh
Co-authored papers 1
Erasme Hospital, Universite Libre de Bruxelles
Co-authored papers 1
Co-authored papers 1
Harvard Medical School
Co-authored papers 1
Harvard University
Co-authored papers 1
University of Texas Southwestern Medical Center
Co-authored papers 1